A 27-year-old previously healthy woman presented to the emergency department in Calgary, Alberta, with shortness of breath, muscle aches and a nonproductive cough that had lasted for 48 hours. During the previous two weeks, the patient had experienced a loss of appetite, fatigue, fever and chills. She reported smoking tobacco and marijuana daily and drinking 12 alcoholic drinks per week; she did not use injection drugs. She took no medications and had no known allergies. Her travel history included a trip to Puerto Escondido in Oaxaca, Mexico, one year earlier and a trip to Vancouver Island, British Columbia, 36 months before presentation. While on Vancouver Island, the patient had spent time hiking and camping in the forested areas of Parksville and Cathedral Grove.
Physical examination showed oxygen saturation of 93% while the patient was breathing ambient air (atmospheric pressure 660 mm Hg), and scattered inspiratory crackles were heard on chest auscultation. The rest of the examination was unremarkable. Laboratory investigations showed a white blood cell count of 21.4 (normal 4.0-11.0) × 10 9 /L, with 17.3 (normal 2.0-8.0) × 10 9 /L neutro phils and 601 (normal 150-400) × 10 9 /L platelets. Radiography of the patient's chest showed multiple pulmonary nodules with mass-like areas of opacification ( Figure 1 ). Computed tomography showed extensive patchy nodular areas of consolidation with early cavitations, pre dom inantly in the upper lobes of the lungs (Figure 2 ). The differential diagnosis included atypical bac terial and fungal infections, septic emboli, metastatic disease and granulomatosis with polyangiitis.
Stained tissue samples from endobronchial and transbronchial biopsies of the right lower lobe of the patient's lung were consistent with Cryptococcus species, and bronchoalveolar lavage cultures were positive for Cryptococcus gattii. The organism was genotyped and found to be strain VGIIa, most frequently isolated from Vancouver Island. Tests of the patient's serum showed cryptococcal antigen at a titre of 1:256. We prescribed oral fluconazole to be taken daily, with follow-up as an outpatient.
We assessed the patient's immune function. Testing for HIV was negative, and her total serum level of immunoglobulin G (IgG) was normal. The patient's IgG subclass levels (subclasses 1, 2, 3 and 4), diphtheria, tetanus and pneu mococcal serologies, and complement levels were normal, as were her isohemagglutinin anti-A (32, normal At two years' follow-up, tests of the patient's serum were negative for cryptococcal antigen, and fluconazole was subsequently discontinued. Spirometry showed that reversible airflow obstruction remained, and chronic parenchymal opacities were visible on radiography of the chest. We have now followed our patient for four years and have seen no evidence of the recurrence of disease. • History of travel, even if several years earlier, to an area endemic for C. gattii should raise suspicion for this etiologic agent; genotyping may help to identify the geographic source of the organism.
• Because colonization with Cryptococcus can occur, a diagnosis of infection requires evidence of pathology or dissemination.
• Infection with C. gattii should be treated with antifungal agents for at least 6 months.
Discussion
Cryptococcus species are environmental fungi, acquired through inhalation, that can cause lifethreatening infections of the pulmonary and central nervous systems. Of the 37 known species, Cryptococcus neoformans and C. gattii are the most commonly identified pathogens, causing a spectrum of disease that includes fever, cough, pneumonia, meningoencephalitis, widespread dis semination and even death. Cryptococcus neo formans usually affects people with HIV, but C. gattii primarily causes disease in immunocompetent patients. The major risk factor for acquiring C. gattii infection is a history of living in or travel to an endemic area. Other risk factors include age greater than 50 years, smoking, use of corticosteroids, and history of cancer or chronic lung disease.
1
The long incubation period of C. neoformans (median 110 months) suggests a period of dormancy before reactivation. 2 However, the median incubation period for all strains of Vancouver Island C. gattii is reported to be 6-7 (range 2-11) months, which is more consistent with a primary infection.
2 Our patient's case highlights the potential for an unusually prolonged incubation period between exposure to C. gattii in an endemic area and clinical presentation. antigen titre) . If the serum level of cryptococcal antigen is elevated, and certainly if neurologic symptoms are present, then a lumbar puncture should be done to exclude involvement of the central nervous system. The 2011 statement from the American Thoracic Society outlines treatment recommendations based on the extent and location of disease. 8 Azole compounds, such as fluconazole, are recommended for treating isolated pulmonary infection, whereas treatment with amphotericin B deoxycholate plus flucytosine is reserved for disseminated disease or involvement of the central nervous system. 8 Treatment should last for at least six months, with the length of therapy tailored to the extent of disease and clinical response.
Endemic areas in North America
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Immunocompetency
Although C. gattii is thought to mostly affect immunocompetent patients, some patients have been found to have immune defects. 6 For this reason, we assessed our patient for a possible immunodeficiency. Our patient had normal IgG isotype levels and normal diphtheria and tetanus serology, suggesting an adequate functional humoral immune response (IgG subclass 1); thus, it was unlikely that she had an immunodeficiency or isotype deficiencies. The results of pneumococcal serology were normal, suggesting adequate IgG subclass 2 response to polysaccharide antigens. Our patient's normal isohemagglutinin titres suggested adequate IgG and immunoglobulin M responses to polysaccharide antigens. Levels of total complement and complement components 3 and 4 were normal, suggesting adequate functional response of the classical pathway. Normal levels of circulating lymphocyte subsets and normal lymphocyte transformation without evidence of clonal aberrancy suggested that there was no defect in cellmediated immunity. The patient's immunoglobulin E level was initially elevated but normalized within three months of treatment, making hyperimmunoglobulin E syndrome (Job syndrome) unlikely. The negative results of our workup for immunodeficiency lends further support to the current understanding that C. gattii mostly affects people with intact immunity.
Geographic source of our patient's infection
Our patient lived in Calgary, but she had hiked and camped in the forested areas of Parksville and Cathedral Grove, BC, which are endemic for C. gattii. Of the C. gattii cases identified in BC from 1999 to 2007, 86.3% were the VGIIa strain, 6 as was the etiologic agent in our patient's infection. Our patient had also visited Mexico; as mentioned previously, one retrospective study identified 8 of 72 cryptococcal cases in Mexico as having been caused by C. gattii, two of which had the VGII genotype. 7 Unfortunately, information regarding VGIIa in these two isolates is unavailable. However, the isolates were from areas other than where our patient had travelled, and as yet there are no reports of the VGIIa strain in the area in Mexico where our patient visited. Thus, the geographic distribution of genotypes makes it highly unlikely that she acquired the infection in Mexico.
MacDougall and colleagues propose that offisland cases of C. gattii infection may be due to fungal elements being carried across the Strait of Georgia from Vancouver Island to the mainland via airborne or anthropogenic dispersal. 6 However, no infections with the VGIIa strain of C. gattii have been shown to be acquired in Calgary, and the distance between Vancouver Island and Calgary (> 1000 km, separated by the Rocky and Coast Mountains) makes local acquisition in the case of our patient unlikely. Physicians caring for patients who have visited an area endemic for C. gattii should be aware of the potential for the disease to develop after a prolonged incubation and include it in their differential diagnosis of pneumonia in an immunocompetent patient.
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